Stay updated on Eli Lilly and Company Press Releases

Sign up to get notified when there's something new on the Eli Lilly and Company Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Eli Lilly and Company Press Releases page

  1. Check
    3 days ago
    Change Detected
    Summary
    The page adds new press releases about FDA approval of Mounjaro and a Zepbound cost study, while several older press releases and campaigns are removed.
    Difference
    8%
    Check dated 2026-08-29T18:04:09.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    A Lipoprotein(a) category was added to the list of topics on the press releases page, expanding the available filters for users seeking releases related to Lipoprotein(a).
    Difference
    0.2%
    Check dated 2026-08-22T13:36:36.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    Adds a press release announcing Lilly filed six lawsuits to shut down the illegal retatrutide black market, highlighting enforcement actions. Removes an earlier press release about the acquisition of Centessa Pharmaceuticals, changing the page’s historical list of corporate developments.
    Difference
    2%
    Check dated 2026-08-15T08:42:35.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The page adds new press releases announcing Q2 2026 financial results and a Breakthrough Therapy designation, and removes older items such as the Q3 dividend announcement and a trial update.
    Difference
    8%
    Check dated 2026-08-08T03:42:15.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    New entries highlight positive retatrutide obesity trial results (TRIUMPH-2 and TRIUMPH-3) and the date of Lilly’s second‑quarter 2026 financial results conference call, expanding the page’s coverage of product news and investor communications. At the same time, older items about a JAK2 inhibitor data release and a Zepbound sleep apnea campaign were removed, narrowing the page’s focus to more current announcements.
    Difference
    8%
    Check dated 2026-07-24T22:09:15.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    Lilly announces the acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and expand its neuroscience portfolio. The page also removes the EBGLYSS FDA-approval release, updating the press releases feed to reflect current news.
    Difference
    4%
    Check dated 2026-07-17T19:03:44.000Z thumbnail image

Stay in the know with updates to Eli Lilly and Company Press Releases

Enter your email address, and we'll notify you when there's something new on the Eli Lilly and Company Press Releases page.